Neutropenia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Neutropenia - Pipeline Review, H2 2016

Neutropenia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Neutropenia - Pipeline Review, H2 2016
Published Sep 28, 2016
93 pages — Published Sep 28, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Neutropenia - Pipeline Review, H2 2016, provides an overview of the Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neutropenia
- The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects
- The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neutropenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neutropenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-lic

  
Source:
Document ID
GMDHC8498IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Neutropenia Overview91
Therapeutics Development101
  Pipeline Products for Neutropenia Overview101
Neutropenia Therapeutics under Development by Companies113
Neutropenia Pipeline Products Glance144
  Late Stage Products141
  Clinical Stage Products151
  Early Stage Products161
  Unknown Stage Products171
Neutropenia Products under Development by Companies181
Neutropenia Companies Involved in Therapeutics Development1916
  Apotex Inc.191
  BeyondSpring Pharmaceuticals, Inc.201
  Biogenomics Limited211
  Cellerant Therapeutics, Inc.221
  Cleveland BioLabs, Inc.231
  Coherus BioSciences, Inc.241
  Dr. Reddy's Laboratories Limited251
  Eurofarma Laboratorios S.A.261
  Ligand Pharmaceuticals, Inc.271
  NAL Pharmaceuticals Ltd.281
  Prolong Pharmaceuticals, LLC291
  Richter Gedeon Nyrt.301
  Sandoz International GmbH311
  Therapeutic Proteins International, LLC321
  Toko Pharmaceutical Industries Co., Ltd.331
  USV Pvt Ltd341
Neutropenia Therapeutics Assessment3511
  Assessment by Monotherapy Products351
  Assessment by Target363
  Assessment by Mechanism of Action393
  Assessment by Route of Administration422
  Assessment by Molecule Type442
Drug Profiles4635
  ACN-8337 Drug Profile461
  CBLB-612 Drug Profile472
  EC-18 Drug Profile491
  filgrastim Drug Profile501
  filgrastim Drug Profile511
  filgrastim Drug Profile521
  filgrastim Drug Profile531
  filgrastim Drug Profile541
  LG-7455 Drug Profile551
  pegfilgrastim Drug Profile561
  pegfilgrastim Drug Profile571
  pegfilgrastim Drug Profile581
  pegfilgrastim Drug Profile591
  pegfilgrastim Drug Profile601
  pegfilgrastim Drug Profile611
  pegfilgrastim Drug Profile622
  pegfilgrastim Drug Profile641
  pegfilgrastim Drug Profile651
  pegfilgrastim Drug Profile661
  pegfilgrastim Drug Profile671
  pegfilgrastim Drug Profile681
  pegfilgrastim (recombinant) Drug Profile691
  plinabulin Drug Profile704
  romyelocel-L Drug Profile743
  ST-7 Drug Profile771
  tamibarotene Drug Profile783
Neutropenia Dormant Projects812
Neutropenia Product Development Milestones839
  Featured News &Press Releases831
    Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case831
    Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case831
    Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study841
    May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication851
    Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets851
    Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim861
    Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study871
    Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701871
    Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program871
    Dec 08, 2015: EMA started the evaluation of Richter s marketing authorisation application for biosimilar pegfilgrastim881
    Dec 07, 2015: Phase III Data Shows Sandoz Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product881
    Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA891
    Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study901
    Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study911
    Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil)911
Appendix922
  Methodology921
  Coverage921
  Secondary Research921
  Primary Research921
  Expert Panel Validation921
  Contact Us921
  Disclaimer931

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Neutropenia - Pipeline Review, H2 2016" Sep 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neutropenia-Pipeline-Review-H2-2016-2088-16611>
  
APA:
Global Markets Direct - Market Research. (2016). Neutropenia - Pipeline Review, H2 2016 Sep 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neutropenia-Pipeline-Review-H2-2016-2088-16611>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.